Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.70156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Mehmet Hocaoǧlu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Machine Learning, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Objective
Proteome‐wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles.
Methods
Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included. Differential proteomic expressions were characterized and followed by hierarchical clustering analysis. Proteomic linear and machine learning models were developed for established disease classification and future lupus prediction and compared to polygenic risk scores. Two additional independent lupus cohorts from Sweden, as part of the Human Protein Atlas (HPA), and from China were used for replication.
Results
In the UK Biobank, 44,173 participants with proteomic data, including 2,063 individuals with at least one autoimmune disease at enrollment, were studied. This included 383 patients with lupus with a mean age of 43.6 ± SD 11.7 years at disease onset. Lupus showed the largest number of dysregulated proteins among autoimmune diseases and clustered with rheumatoid arthritis. Comparison with HPA showed that ~70% of lupus proteomic associations could be replicated with moderate correlation in effect sizes. The machine learning model outperformed the linear model in identifying pre‐existing lupus and generalized well to future lupus prediction. Among patients with lupus on immunomodulatory medications, the model reached ~90% sensitivity at 95% specificity, which was replicated in an independent cohort. Model interpretation highlighted SCARB2, SOD2, CD302, Galectin‐9, and GGT5 proteins with substantial effects on lupus identification.
Conclusion
Proteomic machine learning models show excellent performance for identifying pre‐existing lupus and generalize well for predicting lupus before clinical diagnosis. Model interpretation identified novel candidate biomarkers for lupus. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Lupus Center of Excellence, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Center for Systems Immunology, Departments of Immunology and Computational & Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Division of Rheumatology, Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania.
- Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.
ORCID-Profile: Mehmet Hocaoǧlu, Jishnu Das, Amr H Sawalha
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Hocaoǧlu, M., Das, J., & Sawalha, A. H. (2026). Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification. Arthritis & Rheumatology. https://doi.org/10.1002/art.70156
Vancouver
Hocaoǧlu M, Das J, Sawalha AH. Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification. Arthritis & Rheumatology. 2026. doi:10.1002/art.70156
BibTeX
@article{Hocaolu2026,
author = {Hocaoǧlu, Mehmet and Das, Jishnu and Sawalha, Amr H},
title = {Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70156}
}
EUVIMED